InsidersTradesSigma
Total declarations
Companies
▲ Purchases (24 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
24
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+120.1%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by CHILDS JOHN W, Director. Officer active across 4 companies, notably Veradermics, Inc. Cumulatively, 34 reports have been published. Split: 24 buys · 0 sell. Total volume traded: €105m. Activity tracked since 10 November 2021. The latest transaction was filed on 4 March 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations34 total
28,400 shares@ US$30.426650.0% of flowCommon SharesSEC:0001027035-26-000006
Ideal exit: 29 Nov 2025 (T+270)
28,400 shares@ US$30.42660.055% mcap50.0% of flowCommon SharesSEC:0001027035-26-000006:0
Ideal exit: 29 Nov 2025 (T+270)
294,117 shares@ US$17.0050.0% of flowCommon StockSEC:0001027035-26-000004
Ideal exit: 2 Nov 2026 (T+270)
294,117 shares@ US$17.000.10% mcap50.0% of flowCommon StockSEC:0001027035-26-000004:0
Ideal exit: 2 Nov 2026 (T+270)
73,170 shares@ US$41.002.9% of flowCommon SharesSEC:0001935979-25-000017:0
Ideal exit: 17 Jan 2025 (T+270)
25,000 shares@ US$30.38590.8% of flowCommon SharesSEC:0001935979-25-000018:0
Ideal exit: 29 Nov 2025 (T+270)
29,000 shares@ US$35.94461.0% of flowCommon SharesSEC:0001935979-24-000088:0
Ideal exit: 26 Sept 2025 (T+270)
21,052 shares@ US$47.500.9% of flowCommon SharesSEC:0001935979-24-000078:0
Ideal exit: 29 Jun 2025 (T+270)
28,400 shares@ US$35.66841.0% of flowCommon SharesSEC:0001562180-24-005805:0
Ideal exit: 14 Apr 2025 (T+270)
28,000 shares@ US$35.581.0% of flowCommon SharesSEC:0001562180-24-004529:0
Ideal exit: 24 Feb 2025 (T+270)
28,500 shares@ US$35.17441.0% of flowCommon SharesSEC:0001562180-24-004011:0
Ideal exit: 7 Feb 2025 (T+270)
24,391 shares@ US$41.001.0% of flowCommon SharesSEC:0001562180-24-003494:0
Ideal exit: 17 Jan 2025 (T+270)
73,170 shares@ US$41.002.9% of flowCommon SharesSEC:0001562180-24-003494:2
Ideal exit: 17 Jan 2025 (T+270)
97,560 shares@ US$41.003.9% of flowCommon SharesSEC:0001562180-24-003494:1
Ideal exit: 17 Jan 2025 (T+270)
2,091 sharesCommon SharesSEC:0001562180-24-003337:0
19,412 sharesCommon SharesSEC:0001562180-24-002510:0
48,505 sharesCommon SharesSEC:0001562180-24-000427:0
318,000 shares@ US$22.006.9% of flowCommon SharesSEC:0001562180-23-007253:0
Ideal exit: 1 Jul 2024 (T+270)
136,545 shares@ US$22.003.0% of flowCommon SharesSEC:0001562180-23-007253:1
Ideal exit: 1 Jul 2024 (T+270)
50,000 shares@ US$18.44360.9% of flowCommon SharesSEC:0001562180-23-006632:0
Ideal exit: 26 May 2024 (T+270)
100,000 shares@ US$19.78431.9% of flowCommon SharesSEC:0001562180-23-006204:0
Ideal exit: 30 Apr 2024 (T+270)
2,380,952 shares@ US$10.5026.2% of flowCommon SharesSEC:0001562180-23-003045:0
Ideal exit: 22 Jul 2023 (T+270)
3,900,000 shares@ US$10.5042.9% of flowCommon SharesSEC:0001562180-22-007334:0
Ideal exit: 22 Jul 2023 (T+270)
1,517,500 shares0Common SharesSEC:0001562180-22-007078:0
1,512,500 shares0Common SharesSEC:0001562180-22-007102:0
25 of 34 declarations
About CHILDS JOHN W
John W. Childs is a Board Member at Veradermics, Inc., Biohaven Ltd., and Biohaven Pharmaceutical Holding Co Ltd. He contributes to the governance of all three companies, bringing his expertise in management and strategy. His commitment to innovation is essential for long-term success.
